<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04214951</url>
  </required_header>
  <id_info>
    <org_study_id>ZXH-ITP2019</org_study_id>
    <nct_id>NCT04214951</nct_id>
  </id_info>
  <brief_title>A Study of Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune Thrombocytopenia</brief_title>
  <official_title>A Prospective Observational Study of Switching Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thrombopoietin Receptor Agonists (TPO-ra) are novel treatments for patients with refractory
      Primary Immune Thrombocytopenia (ITP). Rh-TPO and eltrombopag increase the number of
      platelets through different mechanism. If there is cross-resistance between 2 drugs for the
      treatment of adult ITP is still no answer. The purpose of this study is to investigate the
      efficacy and safety of switching eltrombopag and Rh-TPO in adults with ITP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-interventional study. Patients who fail previous steroids and receive rh-TPO and then
      switch to EPAG or vice versa will be enrolled. The reason for switch will be recorded.
      Patients in the rh-TPO group were given rh-TPO 300 U/kg once daily for 21 days, and those in
      the eltrombopag group were given eltrombopag 50mg once daily for 6 weeks. Rh-TPO and
      eltrombopag were terminated any time the platelet counts increased above 100 × 10^9/L in the
      rh-TPO group and 300 × 10^9/L in the eltrombopag group. The efficacy, safety, and
      patient/physician preference will be assessed and compared between the two agents.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate at 6 weeks after switching</measure>
    <time_frame>6 weeks</time_frame>
    <description>The proportion of patients who have reached platelet count ≥ 50×10^9/L at 6 weeks after switching.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatments associated adverse events</measure>
    <time_frame>6 weeks</time_frame>
    <description>Adverse event/serious adverse event associated with study drugs during 6 weeks after switching</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons of switching</measure>
    <time_frame>6 weeks</time_frame>
    <description>Reasons of switching eltrombopag and rh-TPO will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with bleeding events</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of participants with bleeding events of the two groups during 6 weeks after switching</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TOR (time to response)</measure>
    <time_frame>6 weeks</time_frame>
    <description>The time to achieve platelet count ≥ 50×10^9/L after switching.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR (duration of response)</measure>
    <time_frame>6 weeks</time_frame>
    <description>The duration of achieving platelet count ≥ 50×10^9/L after switching.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Corticosteroid-resistant or Relapsed ITP</condition>
  <arm_group>
    <arm_group_label>Recombinant human thrombopoietin (rh-TPO) group</arm_group_label>
    <description>Patients who fail previous steroids and eltrombopag and then switch to Rh-TPO will be enrolled. The reason for switch will be recorded. Patients will be given rh-TPO 300 U/kg once daily for 21 days. Rh-TPO will be terminated any time the platelet counts increased above 100 × 10^9/L. The efficacy, safety, and patient/physician preference will be assessed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eltrombopag group</arm_group_label>
    <description>Patients who fail previous steroids and rh-TPO and then switch to eltrombopag will be enrolled. The reason for switch will be recorded. Patients will be given eltrombopag 50mg once daily for 6 weeks. Eltrombopag will be terminated any time the platelet counts increased above 300× 10^9/L.The efficacy, safety, and patient/physician preference will be assessed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <description>Patients will be given eltrombopag 50mg once daily for 6 weeks.</description>
    <arm_group_label>Eltrombopag group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human thrombopoietin (rh-TPO)</intervention_name>
    <description>Patients will be given rh-TPO 300 U/kg once daily for 21 days.</description>
    <arm_group_label>Recombinant human thrombopoietin (rh-TPO) group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adult ITP patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.18 years or older

        2.Primary ITP

        3.Platelet count ≤ 30 × 109/l

        4.Normal neutrophils, reticulocyte count, creatinine and liver enzyme values

        5.Available follow-up of 2 months at least for each period

        6.Failed initial glucocorticosteroid treatment

        7.Unwillingness to accept splenectomy or failed splenectomy

        -

        Exclusion Criteria:

          1. HIV, hepatitis B or C, Helicobacter pylori infection

          2. Malignancy

          3. Congenital or acquired immunologic deficit

          4. History of thrombosis plus two or more risk factors

          5. Nursing or pregnant women

          6. Abnormal liver and renal functions: AST/ALT/total bilirubin ≥1.5 × ULN, creatinine
             ≥1.5 mg/dl

          7. Severe heart and lung dysfunctions -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao Hui Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao Hui Zhang, MD</last_name>
    <phone>010-88324577</phone>
    <email>zhangxh100@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Institute of Hematology</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011 Apr 21;117(16):4190-207. doi: 10.1182/blood-2010-08-302984. Epub 2011 Feb 16. Review.</citation>
    <PMID>21325604</PMID>
  </reference>
  <reference>
    <citation>Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010 Jan 14;115(2):168-86. doi: 10.1182/blood-2009-06-225565. Epub 2009 Oct 21. Review.</citation>
    <PMID>19846889</PMID>
  </reference>
  <reference>
    <citation>Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 2012 Aug 2;120(5):960-9. doi: 10.1182/blood-2011-12-309153. Epub 2012 Jun 26. Review.</citation>
    <PMID>22740443</PMID>
  </reference>
  <reference>
    <citation>Deutsch VR, Tomer A. Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside. Br J Haematol. 2013 Jun;161(6):778-93. doi: 10.1111/bjh.12328. Epub 2013 Apr 18. Review.</citation>
    <PMID>23594368</PMID>
  </reference>
  <reference>
    <citation>Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013 Jul;98(1):10-23. doi: 10.1007/s12185-013-1382-0. Epub 2013 Jul 3. Review.</citation>
    <PMID>23821332</PMID>
  </reference>
  <reference>
    <citation>Bussel JB, Lakkaraja M. Thrombopoietic agents: there is still much to learn. Presse Med. 2014 Apr;43(4 Pt 2):e69-78. doi: 10.1016/j.lpm.2014.02.008. Epub 2014 Mar 27. Review.</citation>
    <PMID>24680422</PMID>
  </reference>
  <reference>
    <citation>Wörmann B. Clinical indications for thrombopoietin and thrombopoietin-receptor agonists. Transfus Med Hemother. 2013 Oct;40(5):319-25. doi: 10.1159/000355006. Epub 2013 Sep 11. Review.</citation>
    <PMID>24273485</PMID>
  </reference>
  <reference>
    <citation>Wang S, Yang R, Zou P, Hou M, Wu D, Shen Z, Lu X, Li Y, Chen X, Niu T, Sun H, Yu L, Wang Z, Zhang Y, Chang N, Zhang G, Zhao Y. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. Int J Hematol. 2012 Aug;96(2):222-8. doi: 10.1007/s12185-012-1124-8. Epub 2012 Jun 30.</citation>
    <PMID>22753022</PMID>
  </reference>
  <reference>
    <citation>Erickson-Miller CL, Delorme E, Tian SS, Hopson CB, Landis AJ, Valoret EI, Sellers TS, Rosen J, Miller SG, Luengo JI, Duffy KJ, Jenkins JM. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27(2):424-30. doi: 10.1634/stemcells.2008-0366.</citation>
    <PMID>19038790</PMID>
  </reference>
  <reference>
    <citation>Erhardt JA, Erickson-Miller CL, Aivado M, Abboud M, Pillarisetti K, Toomey JR. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol. 2009 Sep;37(9):1030-7. doi: 10.1016/j.exphem.2009.06.011. Epub 2009 Jul 24.</citation>
    <PMID>19631713</PMID>
  </reference>
  <reference>
    <citation>González-Porras JR, Godeau B, Carpenedo M. Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia. Ther Adv Hematol. 2019 May 9;10:2040620719837906. doi: 10.1177/2040620719837906. eCollection 2019. Review.</citation>
    <PMID>31156798</PMID>
  </reference>
  <reference>
    <citation>Cantoni S, Carpenedo M, Mazzucconi MG, De Stefano V, Carrai V, Ruggeri M, Specchia G, Vianelli N, Pane F, Consoli U, Artoni A, Zaja F, D'adda M, Visentin A, Ferrara F, Barcellini W, Caramazza D, Baldacci E, Rossi E, Ricco A, Ciminello A, Rodeghiero F, Nichelatti M, Cairoli R. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers. Am J Hematol. 2018 Jan;93(1):58-64. doi: 10.1002/ajh.24935. Epub 2017 Nov 9.</citation>
    <PMID>28983953</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 28, 2019</study_first_submitted>
  <study_first_submitted_qc>December 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>January 1, 2020</last_update_submitted>
  <last_update_submitted_qc>January 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Xiao Hui Zhang</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Immune Thrombocytopenia</keyword>
  <keyword>Recombinant human thrombopoietin</keyword>
  <keyword>Eltrombopag</keyword>
  <keyword>switching</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

